The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, discusses the updated results of the ALPINE trial (NCT03734016), which compared the BTK inhibitors ibrutinib and zanubrutinib in patients with chronic lymphocytic leukemia (CLL). The findings of this study have been somewhat controversial, as zanubrutinib has shown prolonged progression-free survival (PFS) and superior efficacy to ibrutinib, including in high-risk patients with 17p deletion. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AbbVie, Janssen, BeiGene, LOXO, Novartis, Roche
Research Funding: AbbVie, Janssen, BeiGene
